v3.26.1
Stockholders' Equity and Earnings per Share
9 Months Ended
Jun. 30, 2026
Stockholders' Equity Note [Abstract]  
Stockholders' Equity and Earnings per Share Stockholders’ Equity and Earnings per Share
In March 2024, the Company’s Board of Directors authorized a share repurchase program allowing the Company to purchase up to $2.0 billion of its outstanding shares of common stock, subject to market conditions. In the nine months ended June 30, 2026, the Company purchased 3.3 million shares of its common stock for a total of $882.2 million to complete its authorization under this program.
In May 2026, the Company’s Board of Directors authorized a new share repurchase program allowing the Company to purchase up to $2.0 billion of its outstanding shares of common stock, subject to market conditions. In the nine months ended June 30, 2026, the Company purchased 0.4 million shares of its common stock for a total of $117.8 million. As of June 30, 2026, the Company had $1,882.2 million of availability under this program.
Basic earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding, plus the dilutive effect of restricted stock units and stock options during the periods presented.
    The following illustrates the components of diluted weighted average shares outstanding for the periods indicated:
Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2026202520262025
Weighted average common shares outstanding - basic193,147 193,822 193,971 193,794 
Dilutive effect of restricted stock units and stock options797 1,408 912 1,378 
Weighted average common shares outstanding - diluted193,944 195,230 194,883 195,172 
The potentially dilutive restricted stock units that were antidilutive for the three months ended June 30, 2026 and 2025 were 13 thousand and 1 thousand, respectively. The potentially dilutive restricted stock units that were antidilutive for the nine months ended June 30, 2026 and 2025 were 68 thousand and 92 thousand, respectively.